Project Grant R01HL174521
Award Date
5/15/25
Completion Date
2/28/29
Dollars Obligated
$605K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Mississippi, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $743,302 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The 4-year grant will fund research to investigate how gut microbe-derived lipids, specifically n-acyl amides, can signal through the host G protein-coupled receptor GPR119 to regulate inflammatory and metabolic pathways related to cardiometabolic diseases like...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $732,779 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arizona to investigate the role of the serine-threonine kinase SGK1 in regulating cardiac function and metabolism in cardiometabolic heart failure with preserved ejection fraction (CMET HFPEF). The project aims to determine how cardiac-specific SGK1 influences heart function, metabolism, and inter-organ communication in...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $766,920 to the Augusta University Research Institute, Inc. to conduct research on the mechanisms linking skeletal muscle metabolism and vascular health in obesity. The key objectives are to determine how obesity-induced increases in the enzyme CYP1B1, lipid accumulation in skeletal muscle (myosteatosis), and upregulation of the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), is focused on investigating the role of ceramides as a potential causal mediator in the development of diastolic heart failure. The total award amount is $723,742, with a project period from July 17, 2024 to June 30, 2029. The key objectives of this research project are to determine if ceramides are necessary and sufficient...
This $125,568 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, will support research into the molecular mechanisms governing mitochondrial NAD+ import and regulation. The research aims to elucidate how mitochondria maintain adequate NAD+ levels and how this process may become dysregulated in heart failure, a major global health issue characterized by cardiac bioenergetic abnormalities. Using...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is supporting research to investigate the role of direct mitochondrial lactate oxidation in heart failure. The key objectives are to: 1) quantify direct versus indirect mitochondrial lactate oxidation in healthy hearts and models of cardiac hypertrophy/failure; 2) determine if mitochondrial-localized monocarboxylate transporter 1 (MCT1) is...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will fund a multi-omics investigation into the relationship between adiposity (excess body fat) and lipid levels, and their combined impact on cardiovascular disease risk. The $171,450 award, with a period of performance from September 1, 2024 to August 31, 2026, will be used by the lead researcher, Dr. Dron, and her interdisciplinary team at...
The University of Texas Medical Branch at Galveston received a $132,116 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant, awarded on September 1, 2024, will fund a 4-year research project to study the effects of undernutrition on the development of metabolic syndrome after refeeding. The research aims to determine the role of the FGF21 hormone in predisposing individuals to metabolic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is funded under the Cardiovascular Diseases Research program (CFDA 93.837). The $1,309,340 award will support research at the University of Arizona to investigate the role of coronary microvascular dysfunction as a mechanism contributing to heart failure with preserved ejection fraction (HFpEF). The researchers will use a mouse model of HFpEF induced by a high-fat,...
This $154,568 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to characterize the metabolic and cardiac consequences of lipoic acid deficiency. The goal is to use a mouse model of cardiac-specific lipoylation deficiency to gain insights into the mechanisms by which impaired metabolic flexibility leads to cardiac dysfunction, a hallmark of heart failure. The research team at...